摘要
目的分析紫杉醇联合顺铂治疗晚期乳腺癌的疗效、毒性。方法32例晚期乳腺癌患者，应用紫杉醇联合顺铂治疗，化疗周期为21～30d，中位治疗周期数为4（2～7）。紫杉醇中位剂量为162．5mg／m^2（132．2。200．0mg／m^2）；联合顺铂中位剂量74．5mg／m^2（67．5～85mg／m^2）。结果（1）全组患者有效率为40．6％．其中CR1例，PR12例，SD15例，PD4例（2）既往曾用过蒽环类药物患者有效率为45．8％；KPS评分70～80的有效率为33．3％，KPS评分90。100的有效乎为45．0％。（3）肺转移患者的有效率为60．0％，肝转移患者的有效率为50．0％，软组织转移患者有效率为66．7％，而骨转移未见有效病例。（4）主要毒性反应为恶心呕吐和骨髓抑制。Ⅲ度和Ⅳ度恶心、呕吐发生率为5％。Ⅲ度和Ⅳ度白细胞减低发生率为75％，Ⅲ度和Ⅳ度血红蛋白减低发生率为25％；Ⅲ度和Ⅳ度血小板减低发生率为15％。结论紫杉醇联合顺铂治疗晚期乳腺癌疗效较好，毒性反应可以耐受。
Objective To evaluate the efficacy and toxicity in advanced breast cancer treatment with paclitaxel combination cisplatin. Methods 32 patients with advanced breast cancer received paclitaxel combination cisplatin every three weeks, paclitaxel 162.5 mg/m^2（ 132.2 mg/m^2 ～ 200. 0 mg/m^2 ） , cisplatin 74.5 mg/m^2 （ 67.5 mg/m^2- 85 mg/m^2 ） were used. Efficacy and toxicity was evaluated. Results （ 1 ） The overall response rate in this. group of advanced breast cancer was 40. 6%. There was 1 complete response and 12 partial responses. （2） The response rate was 45.8% for anthracycline - resistant advanced breast cancer. The response rate was 33.3% for the advanced breast cancer whose Karnofsky performance score （KPS）was 70-80, and was 45.0% for the advanced breast cancer whose KPS was 90-100. （3）Responses were seen in lungs, hepatic and soft tissue, and the response rates were 60.0% ,50. 0% ,66.7% , respectively. （3） Toxicity was well tolerated. The main side effects were gastrointestinal and hematlilgic toxicities. Conclusion Paclitaxel combination cisplatin is effective and well tolerated in-patients with advanced breast cancer.
出处
《中国临床保健杂志》
CAS
2007年第3期265-267,共3页
Chinese Journal of Clinical Healthcare
关键词
乳腺肿瘤
紫杉属
顺铂
毒性作用
Breast neoplasms
Taxus
Cisplatin
Toxic actions
